Abstract:
Biotech play Starpharma is five years away from the full commercialisation of its topical HIV/AIDS protection product, chairman Peter Bartels told shareholders yesterday. Speaking at the annual meeting, he said the company recently started human trials in Adelaide of its VivaGel product after approval from the US Federal Drug Administration. He said Starpharma had chosen the more difficult path of seeking clearance for the gel in the US rather than Australia as success overseas would deliver greater kudos and earnings.